Search results
Results from the WOW.Com Content Network
Science & Tech. Shopping
[23] [24] It may be supplied as CBD oil containing only CBD as the active ingredient (excluding THC or terpenes), CBD-dominant hemp extract oil, capsules, dried cannabis, or prescription liquid solution. [4] [20] CBD does not have the same psychoactivity as THC, [25] [26] and can modulate the psychoactive effects of THC on the body if both are ...
CBD is hydroxylated by P450 liver enzymes into 7-OH-CBD. Its metabolites are products of primarily CYP2C19 and CYP3A4 activity, with potential activity of CYP1A1, CYP1A2, CYP2C9, and CYP2D6. [69] Similar to delta-9-THC, a majority of CBD is excreted in feces and some in the urine. [57] The terminal half-life is approximately 18–32 hours. [70]
The use of CBD to treat seizure disorders gained increased attention with a number of media reports in 2012 and 2013, and by the end of 2015 sixteen states had "low-THC, high-CBD" laws in effect. [2] Currently 10 states are considered to have low-THC, high-CBD laws. [1] These laws vary in THC content allowed all the way up to 5% in Georgia and ...
Hemp oil (hemp seed oil) is oil obtained by pressing hemp seeds. Cold pressed, unrefined hemp oil is dark to clear light green in color, with a nutty flavor. The darker the color, the grassier the flavour.
H4CBD (hydrogenated CBD, tetrahydrocannabidiol) is a cannabinoid that was first synthesized by Alexander R. Todd in 1940 derived from the catalytic hydrogenation of cannabidiol. [ 1 ] H2-CBD and 8,9-dihydrocannabidiol have also been referred to as "hydrogenated CBD", which may cause confusion.
CBD shares a precursor with THC and is the main cannabinoid in CBD-dominant Cannabis strains. CBD has been shown to play a role in preventing the short-term memory loss associated with THC. [29] There is tentative evidence that CBD has an anti-psychotic effect, but research in this area is limited. [30] [24]
Each spray delivers a dose of 2.7 mg THC and 2.5 mg CBD. In 2003, GW Pharmaceuticals partnered with Bayer to market the drug under the brand name Sativex. In 2011, GW licensed the rights to commercialise nabiximols to Novartis for Asia (excluding China and Japan ), Africa and the Middle East (excluding Israel ).